Were Newer Antipsychotic Drugs More Effective?
Andrew Scull says a 2005 National Institutes of Mental Health study, published in the New England Journal of Medicine, found that newer antipsychotic drugs were not more effective than an older one. The older first-generation drug was out of patent and cheap. The four newer drugs were still patented and, in some cases, 10 times as expensive.
Most patients did not stay on the drugs. Between 67% and 82% of patients dropped out of the trial, depending on which drug they were on, because the drug was not working or they could not stand the side effects. The newer drugs caused somewhat less tardive dyskinesia, but they brought a new set of side effects. In most cases, people who took the pills gained a lot of weight.
The dropout rate showed real complications in the drugs considered the best available.
#502 – Psychiatry, Insane Asylums, Mental Illness, ECT, Lobotomies, Freud & Jung ·
From the transcript
2005, the National Institutes of Mental Health funds a drug study, not an industry study. And what it wants to look at, the first generation drugs are now out of patent and they're cheap. The second generation are patented and are quite expensive, 10 times as expensive in some cases. So we do something called the KD study, and it's published in the New England Journal of Medicine.
And there are two interesting findings. So you have one first generation antipsychotic drug, one of those very early drugs, and you have four more recent drugs that you're looking at. And
you ask a number of questions. Are the new drugs more efficacious than the old drug? No. Hmm. Were patients willing to tolerate these drugs? And that was a finding that I thought was much underreported at the time. Between 67% and 82% of the patients, depending on which drug they were on, dropped out of the trial because either the drug wasn't working or they couldn't stand the side effects.